Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DERM Journey Medical	$6.11 +3.2%	$5.05	$3.20 ▼ $6.89	$127.64M	0.97	86,430 shs	53,872 shs
PGEN Precigen	$1.59 -3.0%	$1.66	$0.65 ▼ $2.17	$467.53M	1.58	1.19 million shs	827,664 shs
SANA Sana Biotechnology	$1.71 -7.3%	$2.83	$1.52 ▼ $10.50	$384.79M	1.63	3.11 million shs	2.76 million shs
TYRA Tyra Biosciences	$9.77 +1.1%	$12.46	$9.49 ▼ $29.60	$494.39M	1.09	231,937 shs	192,128 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DERM Journey Medical	-3.58%	+6.28%	+11.47%	+41.97%	+52.19%
PGEN Precigen	+1.86%	-8.89%	-5.20%	+125.80%	+13.10%
SANA Sana Biotechnology	+1.93%	-18.36%	-28.76%	+14.60%	-81.55%
TYRA Tyra Biosciences	-5.66%	-11.70%	-19.70%	-31.34%	-40.74%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DERM Journey Medical	2.5326 of 5 stars	3.6	3.0	0.0	2.0	1.7	0.6
PGEN Precigen	3.5374 of 5 stars	3.5	0.0	4.7	1.7	1.7	0.6
SANA Sana Biotechnology	3.1648 of 5 stars	3.4	3.0	0.0	2.3	4.2	0.6
TYRA Tyra Biosciences	2.19 of 5 stars	3.5	1.0	0.0	2.7	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DERM Journey Medical	3.20	Buy	$9.67	58.21% Upside
PGEN Precigen	3.00	Buy	$7.00	340.25% Upside
SANA Sana Biotechnology	2.86	Moderate Buy	$10.80	531.58% Upside
TYRA Tyra Biosciences	3.00	Buy	$30.83	215.59% Upside

Current Analyst Ratings Breakdown

Latest DERM, SANA, TYRA, and PGEN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/28/2025	TYRA Tyra Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$30.00
3/27/2025	DERM Journey Medical	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/20/2025	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/18/2025	SANA Sana Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
3/18/2025	SANA Sana Biotechnology	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$5.00
3/14/2025	SANA Sana Biotechnology	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$7.00
2/18/2025	TYRA Tyra Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
1/23/2025	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $6.00
1/14/2025	PGEN Precigen	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00 ➝ $5.00
1/13/2025	TYRA Tyra Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
1/8/2025	SANA Sana Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$8.00 ➝ $11.00

(Data available from 3/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DERM Journey Medical	$57.77M	2.21	$0.22 per share	28.37	$1.05 per share	5.82
PGEN Precigen	$3.93M	119.12	N/A	N/A	$0.48 per share	3.31
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$1.46 per share	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	$4.74 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DERM Journey Medical	-$3.85M	-$0.94	N/A	N/A	N/A	-31.74%	-132.10%	-26.90%	5/12/2025 (Estimated)
PGEN Precigen	-$95.90M	-$0.48	N/A	N/A	N/A	-3,521.68%	-123.06%	-87.33%	5/13/2025 (Estimated)
SANA Sana Biotechnology	-$283.26M	-$1.16	N/A	N/A	N/A	N/A	-84.22%	-44.97%	5/6/2025 (Estimated)
TYRA Tyra Biosciences	-$69.13M	-$1.61	N/A	N/A	N/A	N/A	-24.56%	-23.31%	4/1/2025 (Estimated)

Latest DERM, SANA, TYRA, and PGEN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/27/2025	Q4 2024	TYRA Tyra Biosciences	-$0.48	-$0.43	+$0.05	-$0.43	N/A	N/A
3/26/2025	Q4 2024	DERM Journey Medical	-$0.22	$0.08	+$0.30	$0.08	$14.21 million	$14.30 million
3/19/2025	Q4 2024	PGEN Precigen	-$0.06	-$0.04	+$0.02	-$0.06	$1.30 million	$1.19 million
3/17/2025	Q4 2024	SANA Sana Biotechnology	-$0.25	-$0.23	+$0.02	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DERM Journey Medical	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DERM Journey Medical	1.81	1.38	1.03
PGEN Precigen	N/A	1.63	1.63
SANA Sana Biotechnology	N/A	4.47	4.47
TYRA Tyra Biosciences	N/A	29.55	29.55

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DERM Journey Medical	7.25%
PGEN Precigen	33.51%
SANA Sana Biotechnology	88.23%
TYRA Tyra Biosciences	84.14%

Insider Ownership

Company	Insider Ownership
DERM Journey Medical	13.16%
PGEN Precigen	44.90%
SANA Sana Biotechnology	31.10%
TYRA Tyra Biosciences	15.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DERM Journey Medical	90	20.89 million	18.14 million	N/A
PGEN Precigen	190	294.04 million	161.37 million	Optionable
SANA Sana Biotechnology	380	225.03 million	153.83 million	Optionable
TYRA Tyra Biosciences	20	50.60 million	42.81 million	Optionable

DERM, SANA, TYRA, and PGEN Headlines

Recent News About These Companies

Tyra Biosciences reports Q4 EPS (43c) vs. (53c) last year

March 28 at 5:52 PM | markets.businessinsider.com

Tyra Biosciences (NASDAQ:TYRA) Sets New 1-Year Low - Here's What Happened

March 28 at 10:47 AM | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives $30.50 Average Price Target from Analysts

March 28 at 3:43 AM | americanbankingnews.com

Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights

March 27 at 4:14 PM | prnewswire.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Recommendation of "Buy" by Analysts

March 23, 2025 | marketbeat.com

Victory Capital Management Inc. Purchases 26,560 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA)

March 21, 2025 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Stock Price Down 4.7% - Should You Sell?

March 18, 2025 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Sees Large Volume Increase - Here's What Happened

March 15, 2025 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Reaches New 12-Month Low - Time to Sell?

March 11, 2025 | marketbeat.com

Tyra Biosciences (TYRA) Expected to Announce Quarterly Earnings on Tuesday

March 11, 2025 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Hits New 12-Month Low - Should You Sell?

March 6, 2025 | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Sees Large Growth in Short Interest

March 4, 2025 | marketbeat.com

4,080,296 Shares in Tyra Biosciences, Inc. (NASDAQ:TYRA) Bought by Alta Partners Management Company L.P.

March 2, 2025 | marketbeat.com

Tyra Biosciences: FGFR1/2 Driven AE Data Spooked The Market

March 1, 2025 | seekingalpha.com

Tyra Biosciences (NASDAQ:TYRA) Hits New 12-Month Low - Time to Sell?

February 28, 2025 | marketbeat.com

Tyra Biosciences to Present at Upcoming Investor Conferences

February 11, 2025 | prnewswire.com

Tyra Biosciences director Nina Kjellson sells $74,323 in stock

February 8, 2025 | msn.com

Tyra Biosciences’ TYRA-430 exerts antitumoral effects in HCC

February 7, 2025 | bioworld.com

Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors

January 31, 2025 | morningstar.com

Tyra Biosciences adds Adele Gulfo to board

January 30, 2025 | msn.com

Tyra Biosciences appoints new board member

January 30, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DERM, SANA, TYRA, and PGEN Company Descriptions

Journey Medical NASDAQ:DERM

$6.11 +0.19 (+3.21%)

Closing price 04:00 PM Eastern

Extended Trading

$6.16 +0.05 (+0.82%)

As of 07:21 PM Eastern

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Precigen NASDAQ:PGEN

$1.59 -0.05 (-3.05%)

Closing price 04:00 PM Eastern

Extended Trading

$1.58 -0.01 (-0.63%)

As of 05:32 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Sana Biotechnology NASDAQ:SANA

$1.71 -0.14 (-7.32%)

Closing price 04:00 PM Eastern

Extended Trading

$1.72 +0.02 (+0.88%)

As of 07:25 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Tyra Biosciences NASDAQ:TYRA

$9.77 +0.11 (+1.14%)

Closing price 04:00 PM Eastern

Extended Trading

$9.77 0.00 (0.00%)

As of 04:28 PM Eastern

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time